MedTrace Logo

Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

NCT04197076 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-07-29

No results posted yet for this study

Summary

This study aims to investigate the efficacy and safety of targeted therapy and chemotherapy±immunotherapy as neoadjuvant therapy in stage IIB-IIIB NSCLC patients.（observational study）

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

anti-PD-1 or anti-PD-L1

immunotherapy anti-PD-1 or anti-PD-L1

DRUG

EGFR-TKI, ALK inhibitor, ROS1 inhibitor

targeted therapy EGFR-TKI, ALK inhibitor, ROS1 inhibitor

DRUG

investigator decided

chemotherapy

Sponsors & Collaborators

  • Shanghai Chest Hospital

    lead OTHER

Principal Investigators

  • Shun Lu · Shanghai Chest Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-25
Primary Completion
2022-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04197076 on ClinicalTrials.gov